Opus Genetics (IRD) said that the FDA has granted Fast Track designation for Phentolamine Ophthalmic Solution 0.75% as a ...

FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 ...

Opus Genetics (IRD) announced that the first pediatric patient was dosed in its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, its ...

Opus Genetics, Inc. announced the dosing of the first pediatric patient in its Phase 1/2 trial for OPGx-LCA5, a gene therapy targeting Leber congenital amaurosis (LCA). Initial results from this ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever 15.0% of Opus Genetics shares are held by institutional investors.

(RTTNews) - Opus Genetics, Inc. (IRD), a clinical-stage ophthalmic biotechnology company, on Tuesday announced that the first pediatric patient has been dosed in its global Phase 1/2 clinical ...

DURHAM, N.C. - Opus Genetics, Inc. (NASDAQ:IRD), a biotechnology firm focusing on gene therapies for inherited retinal diseases, has dosed the first pediatric patient in a Phase... Opus Genetics ...

Opus Genetics (IRD) announced completion of enrollment in the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% ...

Opus Genetics, Inc. (IRD) stock price is 1.17 and Opus Genetics, Inc. (IRD) 10-day simple moving average is 1.18. Opus Genetics, Inc. (IRD) stock price is 1.17 and Opus Genetics, Inc. (IRD ...

Early intervention in pediatric LCA5 patients is particularly important, as it offers the best chance to preserve or restore visual function before the disease progresses," said George Magrath, M.D., ...